|
|
||||||||
In immunocompetent patients, paranasal invasive aspergillosis is rare and has a high recurrence rate. Twenty-three cases of paranasal invasive aspergillosis, involving 14 male and nine female immunocompetent patients were reviewed. All patients were cancer-free, HIV-negative, with normal WBC, and none of the patients had received immunosuppressive therapy or corticosteroids. Mean duration of symptoms before diagnosis was 18 months. Aspergillus flavus was the species most frequently isolated. Surgical debridement was performed in all patients followed by antifungal therapy in 18 patients. Mean follow-up duration was 30 months. Fourteen patients relapsed after a mean of 13 months and required an average of 4.3 admissions for repeat surgical evacuation. In a logistic regression model, relapse was not associated with age, duration of symptoms, clinical findings, extent of disease, or mode of therapy. However, patients who were relapse-free tended to have had complete surgical evacuation followed by antifungal therapy.
This article has been cited by other articles:
![]() |
M. T. Hedayati, A. C. Pasqualotto, P. A. Warn, P. Bowyer, and D. W. Denning Aspergillus flavus: human pathogen, allergen and mycotoxin producer Microbiology, June 1, 2007; 153(6): 1677 - 1692. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Mylona, V Tzavara, S Ntai, M Pomoni, and L Thanos Chronic invasive sinus aspergillosis in an immunocompetent patient: a case report Dentomaxillofac. Radiol., February 1, 2007; 36(2): 102 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Warn, A. Sharp, J. Mosquera, J. Spickermann, A. Schmitt-Hoffmann, M. Heep, and D. W. Denning Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus J. Antimicrob. Chemother., December 1, 2006; 58(6): 1198 - 1207. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |